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The mechanical properties of the soft palate can be associated with breathing abnormalities. Dorsal displacement of the soft palate
(DDSP) is a naturally occurring equine soft palate disorder caused by displacement of the caudal edge of the soft palate. Snoring
and a more serious, sometimes life-threatening, condition called obstructive sleep apnea (OSA) are forms of sleep-related breathing
disorders in humans which may involve the soft palate. The goal of this study was to investigate the effect of injecting the protein
crosslinker genipin into the soft palate to modify its mechanical properties for the treatment of equine DDSP with potential
implications for the treatment of snoring and OSA in humans. Ex vivo experiments consisted of mechanical testing and a wind
tunnel study to examine the effect of genipin on the mechanical properties, displacement, and vibration of equine soft palates. A
pilot in vivo study was completed using DDSP and control horses to test the safety and effectiveness of injecting a genipin reagent
into the soft palate. The wind tunnel testing demonstrated a greater than 50% decrease in transient deformation and a greater than
33% decrease in steady-state vibrations for all doses of genipin tested. Ultimate tensile stress, yield stress, and Young’s modulus
were higher in the genipin-treated distal soft palate specimens by 52%, 53%, and 63%, respectively. The pilot in vivo study showed a
reduction of snoring loudness in all DDSP horses and elimination of DDSP in at least one of three horses. The difficulty of using a
1-meter-long endoscopic injection needle contributed to a consistent overinjection of the equine soft palates, causing excessive
stretching (pillowing) and related degradation of the tissue. These ex vivo and in vivo results demonstrated reduced vibration
amplitude and flaccidity and increased strength of genipin-treated soft palates, suggesting that genipin crosslinking could become
an effective and safe treatment for soft palate related breathing abnormalities.

1. Introduction
Whether the result of repetitive insult or a congenital condition, a flaccid soft palate can be involved in upper airway
obstruction and sound generation in animals and humans.
Dorsal displacement of the soft palate (DDSP) is a naturally
occurring soft palate disorder caused by displacement of
the caudal edge of the soft palate, interfering with normal
expiratory airflow through the nasopharynx (i.e., expiratory
resistive breathing, as opposed to resistive breathing in
human snoring and obstructive sleep apnea which involve
resistance during inhalation), thus producing mechanical

property deficiencies, snoring, and temporary obstruction
of the airway [1]. The displacement can usually be selfcorrected by the animal through swallowing or readjusting
the head position; however, it can occur several times during
a single training session or race causing interruptions to
normal breathing and, consequently, a significant decrease
in performance. Overall, DDSP is estimated to occur in 1040% of competitive horses, especially Thoroughbreds and
Standardbred racehorses [2–8]. Clinical symptoms consist
of a loud gurgling or snoring noise, fluttering of the cheeks
as air is diverted beneath the palate, exercise intolerance,
or commonly described by trainers as “choking down”
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Figure 1: Wind tunnel apparatus. A wind tunnel was constructed to simulate simplified human or equine inhalation or exhalation airflow
(a) consisting of a fan that blew air over the soft palate, an airflow modulator, and a laser micrometer to measure soft palate displacements.
The soft palate was constrained (b) on the hard palate and lateral edges.

or “swallowing their tongue” [2]. Conservative treatments
include tongue-tying during exercise, various types of bits, or
the Cornell Collar. When conservative treatments fail, more
invasive surgical procedures are completed, including the
laryngeal tie-forward procedure, laser staphylectomy, myectomy, palatal sclerotherapy, or a combination of different
procedures, which have a reported 58-78% clinical success
rate [2–9] but without a consensus treatment of choice [10].
With some similarities, snoring is a condition that affects
people of all ages, including 48% of men and 34% of women
[11–13]. Another sleep-related breathing disorder, obstructive
sleep apnea (OSA), is a more serious, and sometimes lifethreatening, condition that occurs in approximately 4.2% of
Americans aged 16 and older [14–18]. Both snoring and OSA
are the result of obstructed airflow during inhalation due to
abnormalities in the geometry of the air passages and the
propensity for aberrant deformation of the soft palate [19, 20].
Current treatments for snoring and OSA include lifestyle
changes, oral appliances, surgery, or minimally invasive
procedures targeted at stiffening the soft palate [21, 22]. Many
of the newer procedures rely to some extent on the formation
of fibrotic scar tissue to stiffen the soft palate [20, 23]. This
fibrotic tissue can be expected to exhibit inferior mechanical
properties and a decrease of structural integrity compared to
normal tissues, leading to the eventual loss of some initial
treatment-related benefits [20–29].
Genipin (GP) is a minimally toxic, protein crosslinker
extracted from the Gardenia jasminoides plant. GP has been
previously investigated with regard to its ability to modify
the mechanical properties of annulus fibrosis tissue in the
intervertebral disc [30, 31]. The study hypothesis was that an
injection of a GP reagent into the soft palate would modify
the mechanical properties of soft palate tissue and thus
reduce aberrant deformation and vibration when subjected
to physiological air flow, while increasing tissue strength.
Further, it was hypothesized that these modifications to the
soft palate tissue could decrease the severity of snoring and
the likelihood of airway collapse, while also increasing the

tissue’s resistance to mechanical degradation. Rather than
generating scar tissue, crosslink augmentation serves to stabilize the tissue, preserving microstructural and compositional
integrity, increasing strength, stiffness, fatigue resistance, and
the energy required to permanently deform (resilience) or fail
(toughness) the tissue, in keeping with its demonstrated effect
in other collagenous tissues [30–32]. The hypothesis was
tested using equine soft palates in ex vivo studies including
wind tunnel testing and mechanical testing and using normal
horses and horses with confirmed DDSP in a small pilot in
vivo study.

2. Methods
2.1. Wind Tunnel Study. A simplified wind tunnel system was
developed to quantitatively measure the displacement and
vibration of soft palate specimens under simulated human
inhalation (Figure 1(a)). Twenty-five equine soft palates were
acquired from a local vendor and divided equally into five
groups: untreated control, GP soaked, and 50 mM, 100 mM,
and 150 mM GP injections. The GP soaked specimens
and untreated controls served as baselines for maximum
crosslinking treatment and for untreated tissue, respectively.
A solution of 0.33 wt. % GP (330mg GP/100ml phosphatebuffered saline, PBS) solution was used to bathe soft palates
to allow for maximal crosslinking in the soaked group. For
the injection treatment groups, genipin was solubilized in
a solution of PBS that included 40% dimethyl sulfoxide
(DMSO) to increase the solubility of the crosslinker. For each
concentration, two 1 ml bilateral injections were delivered
2 cm from the V-notch of the free (distal) edge of the soft
palate (Figure 1(b)). All specimens were covered with PBSsoaked paper towels and placed in plastic bags on a rocker
plate for 24 hours at room temperature to allow ample time
for the GP to diffuse through the tissue and the crosslinking
to take place. When GP reacts with primary amine groups,
it generates a blue pigment that is visible to the naked eye
and serves as a useful indicator of diffusion distance and
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density of crosslinking. After being allowed to react for 24
hours, the soft palate specimens were imaged so that the area
coverage could be analyzed and the distribution of genipin
estimated using ImageJ software (NIH). Preliminary testing
investigated the effects of PBS-DMSO buffer-only treatment
and 37∘ C incubation temperatures. Either condition in the
absence of crosslinker resulted in excessive tissue degradation
making mechanical testing problematic.
Soft palate specimens were mounted into a custom made
C-shaped aluminum clamp that represented the support
provided by the hard palate and lateral connective tissues,
stabilizing the regions around the hard palate but allowing
for free movement of distal tissue (Figure 1(b)). Each soft
palate specimen was subjected to wind tunnel testing prior to
treatment to serve as its own control. The wind tunnel system
produced transient and steady-state wind flow up to 14 m/s
(measured using a Celestron anemometer) over the mounted
soft palate surface to simulate breathing conditions estimated
from human tidal breath volume of 500 ml, period of 2
seconds, nasal cross-sectional area estimate from Smith [33].
Equine airway velocities may be considerably higher based on
the findings of a study using an experimental data validated
computational model [34], which showed peak expiratory
velocity in the region of the epiglottis to be approximately
three times higher. A laser micrometer (Keyence LK-081,
Itaska, IL) was mounted above the sample to measure the
displacement/vibration amplitudes and frequencies. National
Instruments (NI) MAX software was used to capture 10second intervals of data at 1 KHz in three regions of the
soft palate: free edge (0.5 cm from edge), middle (1.5cm
towards hard palate), and hard palate end (1.5cm closer
to hard palate). The change in displacement amplitudes
and vibration frequencies due to treatment were compared
between groups. Additionally, three human cadaveric soft
palates were similarly tested in the wind tunnel with two
bilateral injections of 0.5 ml of the 100 mM genipin solution.
2.2. Mechanical Properties of Soft Palates. A study was completed to determine changes in the mechanical properties of
the soft palate when treated with a buffered 50 mM GP solution. Each of twelve equine soft palates were divided into four
sections cut parallel to the free edge producing two sections
per lateral side, with each section subsequently cut into an
hourglass shape and its dimensions measured. The sections
were separated into three groups: control (untreated), bufferonly injection (0.5 ml of 0.9% saline with 50 mM sodium
phosphate), and buffered genipin injection (0.5 ml of 50 mM
GP in saline-phosphate buffer). Injections were done using
a 25 mm, 22-gauge needle. The needle was inserted at an
angle of approximately 30 degrees from the horizontal in
the approximate center of the specimen, and the reagent
was delivered with uniform pressure over five seconds as
the needle was being extracted from the tissue. All sections
were covered with saline-soaked paper towels and placed on a
rocker plate for 12-15 hours at room temperature to allow time
for GP diffusion and maximal crosslinking prior to testing.
Cyclical hysteresis, stress relaxation, and tensile loading
to failure were evaluated using a materials test system (Test
Resources 100R1000). The cyclical loading consisted of a 10
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N preload combined with 20 cycles of ±3 mm deformation
at a rate of 5 mm/s, allowing the cyclical hysteresis to be
quantified. The hysteresis ratio was defined as the ratio of
the 1st and 20th cycles, and the percent changes in hysteresis
and hysteresis ratio from pretreatment to posttreatment were
calculated. The stress relaxation test involved a 10 N preload
followed by a five-minute hold in displacement to calculate
stress relaxation and relaxation modulus. The changes in
relaxation metrics before and after treatment were calculated.
Finally, tensile load to failure began at zero tensile load and
proceeded at a rate of 1 mm/s to failure, and ultimate tensile
stress (UTS) and corresponding strain, Young’s modulus (E),
toe region modulus, yield stress and strain, toughness, and
resilience were calculated. Outliers, determined by the threesigma rule, were removed from the data sets. The averages
and standard deviations for each parameter were calculated
for the individual test groups. Any parameters with a percent
difference greater than 30% between the buffer-only group
and the GP group were noted. Statistical analysis (described
below) was completed to compare the buffer-only group to
the control group and to compare the buffer-only group to
the GP group.
2.3. Pilot In Vivo Study. The pilot, IACUC approved,
in vivo study served to determine preliminary safety
and effectiveness of injecting equine soft palates with a
buffered GP reagent. Sterile buffer solution—(45 mM 3-[4-(2Hydroxyethyl)-1-piperazyl] propane sulfonic acid phosphate
(EPPS-P) buffer, 8.5 pH, with 10% DMSO to enhance GP
solubility)—was produced by autoclaving and sterile filtering
(Corning, 0.20𝜇m), the solution prior to dispensing into
sterile vials which were sealed until use within a laminar
flow hood. The GP required for a 100 mM concentration
was weighed out into sterile vials and sealed before being
terminally sterilized by gamma irradiation (Steris, 25-50
kGy). Immediately prior to each horse’s soft palate treatment,
2 mL of the buffered solution was added to one GP vial to
produce 2 mL of the 100 mM buffered GP reagent. Based on
the wind tunnel test results, this crosslinker concentration
was essentially double the effective concentration such that
an absence of clinical benefit in treating DDSP horses would
suggest a failure of this mode of treatment, and the absence
of serious morbidity or complications would signal that a safe
concentration can be determined.
The safety phase of this study had three control horses,
and the efficacy phase had three DDSP horses. Prior to
the soft palate treatment, the efficacy phase horses underwent dynamic endoscopic examinations and breathing audio
recordings to confirm DDSP diagnoses and to document
snoring loudness and frequency. The dynamic endoscopic
examinations were conducted by two different equine veterinarians, involving walk, trot, and canter exercise either
on a treadmill or using a lunge line or while harness
racing as permitted by the horse owners. Both of these
tests were repeated after treatment at the same exercise
levels to compare and quantify differences. All six horses
were injected using a 1-meter-long transnasal endoscope by
a single veterinarian with two 1 ml injections of 100 mM
buffered GP solution in the 5:00 and 7:00 positions with the
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epiglottis occupying 6:00. Prior to the soft palate injections,
the veterinarian thoroughly examined each horse and provided standing sedation determining the appropriate dose
of intravenous detomidine and butorphanol based on the
animal’s weight. Also, approximately 10 to 20 mL of 2%
lidocaine was sprayed onto the surface of the caudal margin
of the soft palate through the injection port of the endoscope
to induce topical local anesthesia. After treatment, the horses
were monitored hourly for 72 hours for signs of distress
or difficulty breathing. One week after treatment, the safety
phase horses were euthanized (sedated with intravenous
detomidine (0.02 mg/kg) and butorphanol (0.03 mg/kg) followed by a Fatal Plus (1 mL/4.5kg) injection) and their soft
palates were harvested and immediately placed on dry ice
for storage until further histological analysis. Each palate
produced four samples from the treated regions of tissue
as determined by the visual observation of the blue GP
crosslinking coloration and two samples from an apparently
untreated region. All biopsies were sectioned in the sagittal
plane such that both the mucosal surfaces along with submucosal and muscular components were represented. All tissues
were processed for paraffin infiltration, blocked, sectioned,
stained with H&E, and examined microscopically. Observed
microscopic changes were described as to the extent and
grade of inflammation and fibroplasia using terms including
minimal, mild, moderate, and marked.
The efficacy phase DDSP horses were returned to their
owners 10-14 days after treatment. Ten-second intervals were
selected from the 20-minute audio recordings and analyzed
in the time domain, where gaps in the breathing patterns
indicating potential airway blockages were noted. The audio
recordings were also transformed into the frequency domain
using the fast Fourier Transform (FFT). In the frequency
domain, spectrogram graphs were created in Matlab (MathWorks) and analyzed using the green color channel in
ImageJ to determine changes in amplitude intensities at
various frequencies. High frequency range (500 to 4000 Hzthe Nyquist frequency) and low frequency range (0 to 100 Hz)
changes were expected to correspond to palatal displacement
generated whistling and snoring, respectively [26, 35]. The
frequency domain data were filtered using a moving average
filter. The areas under the frequency domain curve were
calculated using the trapz function in Matlab to represent
the spectral density of the audio file, and then the percent
difference was determined to quantify a difference between
the pretreatment and posttreatment amplitude files. Finally,
a study by Franklin et al. discovered a peak in the 53±24 Hz
range corresponding to an apneic soft palate displacement in
DDSP horses [36]. Therefore, the frequency domain graphs
were analyzed from 20 to 80 Hz before and after treatment to
detect an apnea/displacement related peak.
2.4. Statistical Analysis. Statistical analysis was completed
by first using the F-test to determine whether the sample
variances were equal; if considered equal a Student’s t-test
was used for analysis and if the variances were not considered
equal, a Mann-Whitney U nonparametric test was used.
Statistical significance was considered between groups with
𝛼=0.05.
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3. Results and Discussion
3.1. Wind Tunnel Study. Percentage of tissue crosslinked varied by concentration of GP injected, the control (soaked) had
100% coverage and 50, 100, and 150 mM had approximately
40, 49, and 51% coverage, respectively. The largest amount
of soft palate deformation was seen in the free edge so this
area was the focus for analysis of the effect of crosslinking
treatment. The percent reduction in transient and steadystate displacements is summarized in Figure 2. Treatment
with all GP injection concentrations combined resulted in
average decreases of 51.4% and 33.5% in deformation of
the soft palate when subjected to transient and steady-state
wind flow, respectively. As noted above, the limitations of
this simplified wind tunnel model, especially with regard to
the airflow associated with equine DDSP (possibly 3-fold
higher velocities in expiration), may suggest that the effects
of genipin protein crosslinking in this wind tunnel model
may not accurately reflect the magnitudes of clinical effects
in horses. Fourier analysis of wind tunnel data showed an
average decrease in amplitude for all GP injected treatments
of approximately 24% and an average increase in frequency
of 14 Hz, though the results were not statistically significant.
Samples that were soaked in GP had significantly dampened
vibration during transient and steady-state wind flow compared to the control groups. This group demonstrated the
effects when maximum crosslinking was achieved. Injections
of genipin resulted in more localized crosslinking indicated
by blue coloration extending approximately 2 cm from the
site of injection with a trend of increasing areas of treatment
resulting from increases in crosslinker concentration.
The human soft palate specimens free-end maximum
transient deformations were reduced by an average of
32.4% and maximum steady-state deformations were reduced
by an average of 19.6% compared to pretreatment testing. These pilot human wind-tunnel experiments demonstrated damping magnitudes similar to those in the equine
studies.
3.2. Mechanical Properties of Soft Palates. UTS increased
52% (p=0.021) and ultimate tensile strain decreased 31%
(p=0.006) in the genipin-treated group compared to the
buffer-treated group. Yield stress increased 53% (p=0.017),
and Young’s Modulus increased 63% (p=0.026). The samples
from regions more proximal to the hard palate demonstrated
higher variability in treatment effects. Therefore, results are
listed for all regions and distal regions only (near free edge of
soft palate) in Table 1.
While the genipin treatment altered some of the elasticplastic properties of the soft palate, it did not produce a significant effect on the resilience (the energy required to plastically
deform the tissue) or the toughness (the energy required
to permanently deform the tissue). Additionally, none of
the results from the hysteresis test or the stress relaxation
tests produced statistically significant differences between
the genipin-treated and buffer-only-treated specimens. Thus,
there was no demonstrated effect of the genipin crosslinker
on the viscoelastic properties of the soft palate in this small
study.
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Table 1: Mean differences between genipin-treated specimens (50 mM) compared to buffer-only treatment for each of elastic-plastic and
viscoelastic parameters.
Parameter
Cross-sectional area
Ultimate tensile stress
Ultimate tensile strain
Yield strain
Yield stress
Young’s modulus
Resilience
Toe region modulus
Toughness
1st cycle hysteresis
Change in hysteresis
Hysteresis ratio
Stress relaxation

Distal samples only
11.95% decrease
51.67% increase∗
32.89% decrease
34.57% decrease
53.04% increase∗
63% increase∗
6.43% decrease
118.34% increase
11.99% increase
10.31% increase
1.08% decrease
30.20% increase
4.09% increase

All samples
20.49% decrease
31.20% increase
30.88% decrease∗
30.65% decrease
42.69% increase∗
56.02% increase∗
27.51% decrease
118.33% increase
9.71% increase
23.41% increase
14.88% increase
23.24% increase
9.19% increase

∗ Statistically significant differences (p < 0.05).
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Figure 2: Soft palate deformations. Soft palate free end deformation change from pretreatment to posttreatment in both transient and steadystate flow. Data are mean±SD (n=5).

3.3. Pilot In Vivo Study. All six horses were successfully
treated with two 1 mL transendoscopic injections of the
genipin reagent in the 5:00 and 7:00 locations on the
soft palate. A pillowing expansion of the hemi-palate was
observed upon injection in each case. One safety phase
horse was unintentionally given two 1.5 mL doses due to an
error in calculating the priming volume in the needle and
tubing. One efficacy phase horse experienced mild hypersalivation and a reduced appetite, which subsided within
24 hours.
After returning home, two of the efficacy phase horse
owners reported an improvement in the horse’s breathing
and a decrease in exercise intolerance. The other DDSP
horse had intermittent improvement in the DDSP symptoms.
Postinjection dynamic endoscopic evaluation revealed that
the horse with intermittent improvement still had DDSP,
while one of the horses showing marked improvements no
longer had DDSP. The other horse showing an absence of

DDSP symptoms was not evaluated by dynamic endoscopy
due to logistical issues. All three efficacy phase horses had
a reduction in time domain audio amplitude peaks, as well
as a more uniform breathing pattern, including elimination
of gaps in breathing (typically reflecting a swallowing event
[37]), in the posttreatment graphs compared to pretreatment
(Figure 3). Similarly, spectrograms showed reductions in
amplitudes across a variety of frequencies with treatment,
with the red color representing high amplitudes and the blue
color representing low amplitudes (Figure 4). In particular,
there was a decrease in the high amplitude signals in the
high frequency range for all three horses and in the low
frequency range for two of the horses. Overall, there was
an average 39% reduction in the area of high amplitude red
coloration.
Spectral density in the high frequency range (>500Hz)
was reduced 4-fold in one DDSP horse after treatment (Figure 5(a)) and reduced slightly less than 100% in another horse,
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Figure 3: Typical time domain data. Representative time domain audio data showing (a) a typical pretreatment breathing gap and a
comparison between pretreatment (b) and posttreatment (c).

Figure 4: Typical audio spectrogram data. Representative spectrogram graphs demonstrating a reduction in high amplitude signal across all
frequencies, especially in the high frequency range after treatment.

while spectral density in the low frequency range (<200Hz)
was reduced 27-62% in the three horses (Figure 5(b)). The
horse that did not demonstrate a reduction in high frequency
amplitudes was the horse found to still exhibit DDSP during
the dynamic endoscopic examination. Reduction in high
frequency whistling noises could therefore be associated with
the elimination of palatal displacement in the equine model.
These apnea-related audio results were also confirmed by the
analysis of the Franklin et al. DDSP frequency range [36].
Each of the horses demonstrated peaks in this range before
treatment, but after treatment, the peaks remained only in
the horse found to still exhibit DDSP. Similarly, the consistent
reduction in low frequency audio amplitudes in all three
horses after treatment corresponded to the owner reported
reduction in snoring/breathing loudness.

Histological analysis of the safety phase soft palates
showed no specific trends in the severity or extent of inflammatory infiltrates with regard to the genipin treatment at 7
days after treatment. However, in all treated and untreated
samples, there were moderate-to-extensive regions of tissue
disruption (tearing) toward the mucosal surface and patchy
necrosis toward the middle of the soft palate (Figure 6).
Additionally, biopsies in these more central regions showed
mild-to-moderate inflammatory and fibroplastic responses
in viable tissue. By the presence of tissue disruption and
inflammatory responses in both the treated and untreated
samples, it can be presumed that the delivery method was
responsible for the fibrotic tissue formation. The rapid (12 seconds) injections were associated with a consistently
observed excessive expansion (pillowing) of the soft palate
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Figure 5: Typical frequency domain data. (a) Representative high frequency domain graph from 500 to 4000 Hz showed a decrease in
posttreatment amplitudes related to a reduction in soft palate whistling sounds. (b) Representative low frequency domain graph from 0
to 200 Hz showed a decrease in posttreatment amplitudes related to a reduction in loudness of snoring sounds and vibrations.
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expanded vessels in submucosa
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Figure 6: Histological observations from safety phase soft palates. There were moderate-to-extensive regions of tissue disruption and patchy
necrosis with mild-to-moderate inflammatory and fibroplastic responses in viable tissue in both treated and untreated regions of the soft
palate, believed to be due to the consistently observed excessive expansion of the soft palate (pillowing) during the injections.

tissues. The outer regions of the tissue would have undergone
the most strain corresponding to the regions of tissue tearing.
These histologic observations suggest that future injections
should be done with a decreased reagent volume and a slower
rate of injection to promote flow and diffusion of the reagent
through the tissue rather than creating a sudden bolus of
reagent in the middle of the tissue. It is also a consideration
that the overstretching of the tissue and subsequent healing
response may have contributed to the overall success of the
treatment in the DDSP horses. However, laser palatoplasty
induced inflammation and fibrosis that was observed in a
study by Alkabes et al. [38] resulted in a significant decrease in

soft palate elastic modulus. This finding may suggest that the
fibrosis and inflammation resulting from the tissue stretching
(at the time of injection) in the current study may have
reduced the palatal stiffening effects seen in the efficacy phase
horses.
The histological analyses were conducted on the safety
phase horses exclusively at 7 days after treatment. This
constitutes a limitation of the present study considering that
other similar soft palate treatment studies evaluated changes
to the treated tissues from 2 to 45 days [38] and from 2 weeks
to 6 months [39] after treatment. In particular, it would be
valuable to have audio and dynamic endoscopic data from
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efficacy phase horses at later time-points corresponding to
histological data from sacrificed horses. Alkabes et al. [38]
found that edema and inflammation decreased from day 2
to day 45. Therefore having later time-points in subsequent
studies may make it possible to deduce the relative contribution of tissue stretching induced inflammation and fibrosis
to the increased palatal stiffness and reduced palate displacements observed in this first study. Likewise, minimization or
elimination of tissue overstretching during injection in future
studies would enable assessment of the genipin crosslinking
effect alone in the prevention of palate flipping, breathing
disruption, and snoring loudness. A longer period of postinjection testing would also be important to assess the durability of these presumed permanent covalent bond induced
effects.
The pilot in vivo study demonstrated that injecting
genipin is feasible and effective in reducing snoring loudness
and preventing soft palate displacements. The treatment was
determined to be safe; however, excessive expansion of the
soft palate tissue during the injection should be avoided.
Aberrant injections would be less likely if this treatment was
applied to human soft palates because of the difference in
accessibility. All of the DDSP horses exhibited a reduction in
snoring loudness, and at least one of the DDSP horses was
found to no longer exhibit DDSP. An injectable treatment
utilizing protein crosslinking may also provide the added
potential benefits of being easier to administer, less expensive,
more durable, and less harsh compared to current treatments
and emerging minimally invasive approaches for treating
equine DDSP.

4. Conclusions
The genipin reagent injection demonstrated a reduction in
soft palate deformation and vibration amplitude and an
increase in tissue strength, stiffness, and stability based on the
results from the mechanical testing and wind tunnel studies.
Pilot in vivo studies demonstrated that with appropriate
delivery to the soft palate tissues the treatment could be safe
and effective in reducing snoring loudness and preventing
soft palate apneic displacements. These results suggest that
genipin-based treatments should be further evaluated for
equine-scaled air flow and duration of effect as it could
become an effective and safe treatment for equine DDSP and
other upper airway breathing disorders that involve a flaccid
soft palate.
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